Welcome to our dedicated page for TG THERAPEUTICS SEC filings (Ticker: TGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TG Therapeutics' SEC filings document a commercial-stage biotechnology issuer whose common stock trades on the Nasdaq Capital Market under TGTX. The filings cover operating results and financial condition, BRIUMVI product revenue and revenue guidance, license, royalty and other commercialization revenue, and research and development spending tied to its B-cell disease pipeline.
Material-event filings also record capital-structure actions such as senior secured credit financing, repayment of prior term loans, and related borrowing terms. Proxy materials disclose board elections, executive compensation, equity awards, shareholder voting matters, and governance practices for the public company.
TG Therapeutics reported strong year-over-year commercial progress driven by BRIUMVI sales and improved profitability. For the six months ended June 30, 2025 the company recognized $262.0 million of total revenue, primarily product revenue from U.S. BRIUMVI sales, compared with $136.9 million in the prior-year period. GAAP net income was $33.2 million for the six months and $28.2 million for the quarter, reversing prior-year losses.
The balance sheet shows current assets of $663.96 million including cash, cash equivalents and investment securities the company states as $278.9 million available with management anticipating liquidity for more than twelve months. Working capital increased: accounts receivable rose to $231.5 million and inventory to $155.2 million. The company has a secured term loan with a carrying amount of $245.0 million (non-current) and an accumulated deficit of approximately $1.5 billion. Results reflect ongoing commercialization of BRIUMVI and related license revenue from ex-U.S. partner Neuraxpharm.